Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
Crescent Biopharma, Inc. (CBIO)
Last crescent biopharma, inc. earnings: 11/7 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
catalystbiosciences.com/investors
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced completion of dosing and the 30-day follow-up period for its Phase 2b trial of SQ dalcinonacog alfa (DalcA). “We are pleased to have successfully completed the DalcA Phase 2b trial during this challenging pandemic and remain on track to report final results later this quarter,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. ”Interim trial data presented at European Association for Haemophilia and Allied Disorders (EAHAD) 2020 earlier this year clearly demonstrated the potential for DalcA to significantly change the treatment paradigm in hemophilia B; we look forward to continuing its development.” The open-label Phase 2b study was designed to evaluate the ability of DalcA to maintain steady state protective FIX lev
Show less
Read more
Impact Snapshot
Event Time:
CBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBIO alerts
High impacting Crescent Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CBIO
News
- Crescent Biopharma (NASDAQ:CBIO) was given a new $32.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Crescent Biopharma (NASDAQ:CBIO) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Crescent Biopharma (NASDAQ:CBIO) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e-)" rating on the stock.MarketBeat